Form 4: Corcept Therapeutics Chief Development Officer Exercises Options and Sells Shares in Pre-Arranged Transaction

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold 20,000 shares of common stock for approximately $1.45 million, reducing his direct beneficial ownership.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), executed transactions involving company stock on June 10, 2025.
• He exercised stock options to acquire 20,000 shares of common stock at an exercise price of $21.65 per share.
• Concurrently, he sold a total of 20,000 shares of common stock in two batches.
• The first batch of 16,918 shares was sold at a weighted average price of $72.3644 per share, with actual sale prices ranging from $71.70 to $72.695.
• The second batch of 3,082 shares was sold at a weighted average price of $72.7494 per share, with actual sale prices ranging from $72.70 to $72.97.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2024.
• Following these transactions, William Guyer's direct beneficial ownership of common stock decreased from 25,487 shares to 5,487 shares.
• His remaining stock options (derivative securities) amount to 390,000 shares.

Sentiment

Score: 5

Explanation: Neutral. The transaction is an exercise and sell of options under a pre-arranged 10b5-1 plan, which is a common liquidity event for executives and not necessarily indicative of negative sentiment towards the company's future prospects. It is not a new purchase, which would typically be viewed more positively.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned sale for liquidity or diversification rather than a reaction to immediate market conditions.
• The exercise of options at $21.65 and subsequent sale at prices over $72 demonstrates significant value realization from the vested options.

Negatives

• The sale of 20,000 shares by a Chief Development Officer reduces his direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a common practice for executives to monetize vested stock options for personal financial planning.

Stakeholder Impact

• Shareholders: The sale by a key executive could be perceived neutrally to slightly negatively, as it reduces his direct equity stake, though it is a common liquidity event for executives and was pre-planned.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, CORT, SEC Form 4, Insider Trading, Stock Options, Share Sale, William Guyer, Chief Development Officer, 10b5-1 Plan, Beneficial Ownership